Cadrenal Therapeutics Faces Delisting Notice

TL;DR

CADX might get delisted, filing an 8-K for listing rule issues.

AI Summary

Cadrenal Therapeutics, Inc. filed an 8-K on March 5, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The company is also filing financial statements and exhibits as part of this report. The specific reason for the potential delisting or failure to meet listing standards is not detailed in the provided text.

Why It Matters

This filing indicates potential issues with Cadrenal Therapeutics' compliance with stock exchange listing requirements, which could lead to the company's shares being delisted.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading status and investor confidence.

Key Players & Entities

• Cadrenal Therapeutics, Inc. (company) — Registrant
• March 5, 2024 (date) — Date of earliest event reported
• 001-41596 (company) — Commission File Number
• 88-0860746 (company) — IRS Employer Identification No.
• 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 (company) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CVKD The Nasdaq Stock Mar
• $1.00 — ved by meeting the minimum bid price of $1.00 per share (the "Price Requirement") for

Filing Documents

• ea0201254-8k_cadrenal.htm (8-K) — 28KB
• 0001213900-24-020181.txt ( ) — 199KB
• cvkd-20240305.xsd (EX-101.SCH) — 3KB
• cvkd-20240305_lab.xml (EX-101.LAB) — 33KB
• cvkd-20240305_pre.xml (EX-101.PRE) — 22KB
• ea0201254-8k_cadrenal_htm.xml (XML) — 4KB

01 Notice of Delisting or Failure to

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on September 6, 2023, Cadrenal Therapeutics, Inc. (the "Company") received a letter from The Nasdaq Stock Market ("Nasdaq") stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the "Rule"),. The notification received had no immediate effect on the Company's continued listing on the Nasdaq Capital Market, subject to the Company's compliance with the other continued listing requirements. On March 5, 2024, the Company received written notification from Nasdaq granting the Company's request for a 180-day extension or until September 3, 2024 to regain compliance with the Rule. Compliance is generally achieved by meeting the minimum bid price of $1.00 per share (the "Price Requirement") for a minimum of 10 consecutive business days. However, the Staff may, in its discretion, require a Company to satisfy the applicable Price Requirement for a period in excess of 10 consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance. If the Company does not regain compliance with the Price Requirement by September 3, 2024, Nasdaq will provide written notification to the Company that its common stock will be delisted. At that time, the Company may appeal the relevant delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq Listing Rules. However, there can be no assurance, if the Company does appeal the delisting determination by Nasdaq to the hearings panel, that such appeal would be successful. The Company intends to monitor the closing bid price of its common stock and, if appropriate, consider further available options to regain compliance with the Rule, including effecting a reverse stock split, if necessary. Nasdaq's extension notice has n

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document) 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 5, 2024 CADRENAL THERAPEUTICS, INC. By: /s/ Quang Pham Name: Quang Pham Title: Chairman and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR